Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

77
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
77
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

55
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
55
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Cerebral venous thrombosis-related stroke in India: Clinical patterns, risk factors, and outcomes from the hospital-based stroke registry programme.

The Indian journal of medical research·2026
Same author

Outcomes of Early Versus Later Anticoagulation in Asian Atrial Fibrillation-Related Stroke: ELAN Subgroup Analysis.

Journal of stroke·2026
Same author

Multimorbidity among indigenous tribal communities in Kerala, India: a cross-sectional study (2022-2024).

The Lancet regional health. Southeast Asia·2026
Same author

Time-Dependent Efficacy of Thrombolysis Before Thrombectomy: Registry of Stroke Care Quality (RES-Q).

Stroke·2026
Same author

Comparison of primary and secondary stroke outcomes between government and private healthcare institutions: insights from the SPRINT India trial.

Frontiers in stroke·2026
Same author

Asundexian for Secondary Stroke Prevention.

The New England journal of medicine·2026

関連する実験動画

Updated: Sep 10, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

高密度リポタンパク質の多様性は 脳卒中のリスク因子として 良くも悪くも

Soumya Krishnamoorthy1, S Manjunatha2, Deepa Damayanthi3

  • 1Comprehensive Stroke Care Program, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.

Journal of lipid research
|August 21, 2025
PubMed
まとめ

高密度脂質コレステロール (HDL-C) レベルだけでは,脳卒中リスクを完全に予測することはできません. HDL を探索する

キーワード:
動脈硬化症コレステロールの流出HDLの機能HDL 粒子の濃度高密度の脂質タンパク質脳卒中

さらに関連する動画

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.5K

関連する実験動画

Last Updated: Sep 10, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.5K

科学分野:

  • 心血管科学
  • 神経科学
  • 脂質代謝

背景:

  • 高密度脂質 (HDL) は,心血管疾患と動脈形成におけるその役割について研究されている.
  • 血のHDLコレステロール (HDL-C) レベルは脳卒中リスクと逆の関係を示していますが,この関連は複雑です.
  • HDL粒子の異質性と機能性は,脳卒中のリスクを予測する上で重要であるが,十分に研究されていない側面である.

研究 の 目的:

  • HDLと脳卒中の多面的な関係に関する現在の文献をレビューする.
  • 脳卒中の病理学におけるコレステロールレベルを超えたHDL機能の重要性を強調する.
  • HDLの異質性とその脳卒中への影響に関する研究におけるギャップを特定する.

主な方法:

  • HDLと脳卒中に関する現代の研究の文献レビュー.
  • HDLの異質性に寄与する要因の分析 (例えば,亜種,脂質/タンパク質含有量).
  • 脳卒中の予防におけるHDLの機能性 (例えば,抗酸化,抗炎症) の検討

主要な成果:

  • 脳卒中のリスクを予測するには,HDL-Cレベルだけでは不十分です.
  • HDL粒子の異質性は,大動脈保護機能と潜在的に脳卒中保護機能に大きな影響を及ぼします.
  • HDLの抗酸化および抗炎症性は,動脈硬化に関連した脳卒中を予防するために不可欠である可能性があります.

結論:

  • 脳卒中のリスクを総合的に評価するには,HDLの多様な機能を理解することが不可欠です.
  • 将来の研究は,脳卒中リスクの予測を洗練するために,HDL亜種と機能的測定に重点を置くべきです.
  • HDLの機能をターゲットにすることで,脳卒中の予防のための新しい治療戦略を提供することができます.